Lionel D’Almeida
Senior Partner
MumbaiPractice Area
What intrigues me about the capital markets practice is the level of exposure that a lawyer can benefit from - not just from the legalities surrounding fund raising, but also the legal concerns applicable to varying businesses and the related processes.
Lionel D’Almeida is developing a strong profile in this space. Clients value his high levels of availability and skill in coordinating between different parties.
Chambers & Partners Global (2021)Lionel D’Almeida has 15 years of experience and is a member of the Firm’s Capital Markets group. Lionel focusses primarily on corporate finance, which entails advising on domestic and international capital market transactions, including public offers of equity and debt, rights issues and qualified institutions placements, as well as bulk and block deals, open offers, buy-back offers and delisting offers. He also advises and represents clients on various aspects of securities law, including proceedings before the Securities and Exchange Board of India.
WORK HIGHLIGHTS
-
On its USD 517 million IPO
-
On its USD 715 million IPO
-
On KFin Technologies’ USD 180 million IPO
-
On (i) Max Healthcare Institute’s direct listing of equity shares (ii) followed by its USD 157 million QIP On KKR’s exit from Max Healthcare Institute, which concluded with a USD 1.15 billion block
-
On its USD 21 billion buyback of equity shares
-
On its (i) USD 1.95 billion further public offering (ii) USD 250 million QIP
-
On its USD 517 million IPO
-
On its USD 715 million IPO
-
On KFin Technologies’ USD 180 million IPO
-
On (i) Max Healthcare Institute’s direct listing of equity shares (ii) followed by its USD 157 million QIP On KKR’s exit from Max Healthcare Institute, which concluded with a USD 1.15 billion block
-
On its USD 21 billion buyback of equity shares
-
On its (i) USD 1.95 billion further public offering (ii) USD 250 million QIP
-
On its USD 517 million IPO
-
On its USD 715 million IPO
-
On KFin Technologies’ USD 180 million IPO
-
On (i) Max Healthcare Institute’s direct listing of equity shares (ii) followed by its USD 157 million QIP On KKR’s exit from Max Healthcare Institute, which concluded with a USD 1.15 billion block
-
On its USD 21 billion buyback of equity shares
-
On its (i) USD 1.95 billion further public offering (ii) USD 250 million QIP
-
On its USD 517 million IPO
-
On its USD 715 million IPO
-
On KFin Technologies’ USD 180 million IPO
-
On (i) Max Healthcare Institute’s direct listing of equity shares (ii) followed by its USD 157 million QIP On KKR’s exit from Max Healthcare Institute, which concluded with a USD 1.15 billion block
-
On its USD 21 billion buyback of equity shares
-
On its (i) USD 1.95 billion further public offering (ii) USD 250 million QIP
-
On its USD 517 million IPO
-
On its USD 715 million IPO
-
On KFin Technologies’ USD 180 million IPO
-
On (i) Max Healthcare Institute’s direct listing of equity shares (ii) followed by its USD 157 million QIP On KKR’s exit from Max Healthcare Institute, which concluded with a USD 1.15 billion block
-
On its USD 21 billion buyback of equity shares
-
On its (i) USD 1.95 billion further public offering (ii) USD 250 million QIP
-
On its USD 517 million IPO
-
On its USD 715 million IPO
-
On KFin Technologies’ USD 180 million IPO
-
On (i) Max Healthcare Institute’s direct listing of equity shares (ii) followed by its USD 157 million QIP On KKR’s exit from Max Healthcare Institute, which concluded with a USD 1.15 billion block
-
On its USD 21 billion buyback of equity shares
-
On its (i) USD 1.95 billion further public offering (ii) USD 250 million QIP
-
On its USD 517 million IPO
-
On its USD 715 million IPO
-
On KFin Technologies’ USD 180 million IPO
-
On (i) Max Healthcare Institute’s direct listing of equity shares (ii) followed by its USD 157 million QIP On KKR’s exit from Max Healthcare Institute, which concluded with a USD 1.15 billion block
-
On its USD 21 billion buyback of equity shares
-
On its (i) USD 1.95 billion further public offering (ii) USD 250 million QIP
-
On its USD 517 million IPO
-
On its USD 715 million IPO
-
On KFin Technologies’ USD 180 million IPO
-
On (i) Max Healthcare Institute’s direct listing of equity shares (ii) followed by its USD 157 million QIP On KKR’s exit from Max Healthcare Institute, which concluded with a USD 1.15 billion block
-
On its USD 21 billion buyback of equity shares
-
On its (i) USD 1.95 billion further public offering (ii) USD 250 million QIP
-
On its USD 517 million IPO
-
On its USD 715 million IPO
-
On KFin Technologies’ USD 180 million IPO
-
On (i) Max Healthcare Institute’s direct listing of equity shares (ii) followed by its USD 157 million QIP On KKR’s exit from Max Healthcare Institute, which concluded with a USD 1.15 billion block
-
On its USD 21 billion buyback of equity shares
-
On its (i) USD 1.95 billion further public offering (ii) USD 250 million QIP
-
On its USD 517 million IPO
-
On its USD 715 million IPO
-
On KFin Technologies’ USD 180 million IPO
-
On (i) Max Healthcare Institute’s direct listing of equity shares (ii) followed by its USD 157 million QIP On KKR’s exit from Max Healthcare Institute, which concluded with a USD 1.15 billion block
-
On its USD 21 billion buyback of equity shares
-
On its (i) USD 1.95 billion further public offering (ii) USD 250 million QIP
-
On its USD 517 million IPO
-
On its USD 715 million IPO
-
On KFin Technologies’ USD 180 million IPO
-
On (i) Max Healthcare Institute’s direct listing of equity shares (ii) followed by its USD 157 million QIP On KKR’s exit from Max Healthcare Institute, which concluded with a USD 1.15 billion block
-
On its USD 21 billion buyback of equity shares
-
On its (i) USD 1.95 billion further public offering (ii) USD 250 million QIP
RECENT RECOGNITION
2025
2024
2023
2022
Chambers & Partners Asia–Pacific
Ranked for Capital Markets: Equity
Asialaw Profiles
‘Distinguished Practitioner’ for Capital Markets
Chambers & Partners Asia–Pacific
Ranked for Capital Markets: Equity
Chambers & Partners Global
Ranked for Capital Markets: Equity
IFLR1000
‘Highly Regarded’ for Capital Markets: Debt and Equity
Legal 500 Asia Pacific
Recommended for Capital Markets
Asialaw Profiles
‘Notable Practitioner’ for Capital Markets
Chambers & Partners Asia–Pacific
Ranked for Capital Markets: Equity
Chambers & Partners Global
Ranked for Capital Markets: Equity
IFLR1000
‘Highly Regarded’ for Capital Markets: Structured Finance and Securitisation
Legal 500 Asia Pacific
Recommended for Capital Markets
Legal Era
Named a Leading Lawyer for Capital Markets
Asialaw Profiles
‘Notable Practitioner’ for Capital Markets
Chambers & Partners Asia–Pacific
Ranked for Capital Markets: Equity
Chambers & Partners Global
‘Up and Coming’ Capital Markets Lawyer
IFLR1000
‘Highly Regarded’ for Capital Markets: Structured Finance and Securitisation
Legal 500 Asia Pacific
Recommended for Capital Markets
Legal Era
Named a Leading Lawyer for Capital Markets
RECENT RECOGNITION
Chambers & Partners Asia–Pacific
Ranked for Capital Markets: Equity
Asialaw Profiles
‘Distinguished Practitioner’ for Capital Markets
Chambers & Partners Asia–Pacific
Ranked for Capital Markets: Equity
Chambers & Partners Global
Ranked for Capital Markets: Equity
IFLR1000
‘Highly Regarded’ for Capital Markets: Debt and Equity
Legal 500 Asia Pacific
Recommended for Capital Markets
Asialaw Profiles
‘Notable Practitioner’ for Capital Markets
Chambers & Partners Asia–Pacific
Ranked for Capital Markets: Equity
Chambers & Partners Global
Ranked for Capital Markets: Equity
IFLR1000
‘Highly Regarded’ for Capital Markets: Structured Finance and Securitisation
Legal 500 Asia Pacific
Recommended for Capital Markets
Legal Era
Named a Leading Lawyer for Capital Markets
Asialaw Profiles
‘Notable Practitioner’ for Capital Markets
Chambers & Partners Asia–Pacific
Ranked for Capital Markets: Equity
Chambers & Partners Global
‘Up and Coming’ Capital Markets Lawyer
IFLR1000
‘Highly Regarded’ for Capital Markets: Structured Finance and Securitisation
Legal 500 Asia Pacific
Recommended for Capital Markets
Legal Era
Named a Leading Lawyer for Capital Markets